Therapeutic targets of current FD-specific approved and future treatments. AGAL/GLA: AGAL, loss of function results in FD; A4GALT: α-1,4-galactosyltransferase; B3GALNT1: β-1,3-N-acetylgalactosaminyltransferase 1; B4GALT6: β-1,4-galactosyltransferase 6; GBA: glucosylceramidase β, loss of function results in Gaucher disease; GLB1: galactosidase-β1, loss of function results in GM1 gangliosidosis; HEXA: hexosaminidase subunit α, loss of function results in GM2 gangliosidosis.